Patents Assigned to MedImmune, LLC
  • Publication number: 20190040143
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.
    Type: Application
    Filed: June 29, 2018
    Publication date: February 7, 2019
    Applicant: MedImmune, LLC
    Inventors: Partha S. Chowdhury, David Tice, Zhan Xiao, Philipp Steiner, Krista Kinneer, Marlon Rebelatto
  • Publication number: 20190016787
    Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.
    Type: Application
    Filed: January 25, 2018
    Publication date: January 17, 2019
    Applicant: MEDIMMUNE, LLC
    Inventors: Bret SELLMAN, Christine TKACZYK, Partha S. CHOWDHURY, Lei HUA, Peter PAVLIK, Rebecca BUONPANE, Chew-Shun CHANG
  • Publication number: 20190002540
    Abstract: The present invention provides for methods of preventing and/or treating S. aureus-associated bacteremia and sepsis, and methods for preventing and/or treating S. aureus-associated pneumonia in immunocompromised patients using anti-S. aureus alpha-toxin (anti-AT) antibodies. Also provided are methods of reducing S. aureus bacterial load in the bloodstream or heart of a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof. Methods of reducing S. aureus bacterial agglutination and/or thromboembolic lesion formation in a mammalian subject comprising administering to the subject an effective amount of an isolated anti-S. aureus alpha toxin (anti-AT) antibody or antigen-binding fragment thereof, are also provided. Also provided are methods of preventing or reducing the severity of S. aureus associated pneumonia in an immunocompromised mammalian subject.
    Type: Application
    Filed: December 18, 2017
    Publication date: January 3, 2019
    Applicant: MedImmune, LLC
    Inventors: Brett R. SELLMAN, Christine TKACZYK, Melissa HAMILTON, Lei HUA
  • Patent number: 10160812
    Abstract: The present invention relates to anti-HER2 binding molecules (e.g., antibodies and antigen binding fragments thereof), derived HER2-binding molecules (e.g., bispecific anti-HER2 antibodies), and antibody-drug conjugates (ADC) that bind the extracellular domain of the HER2 receptor. Also provided are pharmaceutical formulation comprising the disclosed compositions and method for the treating diseases associated with HER2-mediated signal transduction.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: December 25, 2018
    Assignee: MedImmune, LLC
    Inventors: John Li, Nazzareno Dimasi, Steven Coats, Melissa Damschroder, Changshou Gao, Godfrey Rainey, Cuihua Gao, Dorin Toader, Lakshmaiah Gingipalli, Fengjiang Wang, Ryan Fleming, Binyam Bezabeh, Andy Qingan Yuan, Srinath Kasturirangan
  • Patent number: 10159745
    Abstract: Novel tubulysin derivatives which may be useful as cytotoxic agents to provide therapeutic benefits in the treatment of various types of cancers, alone, as drug conjugates or in combination with other chemotherapies are provided.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: December 25, 2018
    Assignee: MedImmune, LLC
    Inventors: Lakshmaiah Gingipalli, Dorin Toader, Fengjiang Wang
  • Patent number: 10150815
    Abstract: The disclosure provides humanized anti-OX40 antibodies. Also provided are methods of making such antibodies, and methods of use, e.g., treatment of cancer.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: December 11, 2018
    Assignee: MEDIMMUNE, LLC
    Inventors: Scott A. Hammond, Michael Oberst, Qun Du, Melissa Damschroder
  • Publication number: 20180280622
    Abstract: This invention discloses pre-filled syringes and adjustable or movable dose limit fittings that cooperate with the plunger rod to titrate dosage, and methods for using same.
    Type: Application
    Filed: October 3, 2016
    Publication date: October 4, 2018
    Applicant: MEDIMMUNE, LLC
    Inventors: Bo LI, Daniel HEINSBERGEN, Janardhanan Anand SUBRAMONY
  • Patent number: 10077319
    Abstract: This application provides anti-PCSK9˜GLP-1 fusions and methods for use.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: September 18, 2018
    Assignees: MedImmune, LLC, MedImmune Limited
    Inventors: Anthony Celeste, Matthieu Chodorge, Andrew Buchanan, Cristina Rondinone, Joseph Grimsby, Peter Ravn, Jonathan Seaman, David Fairman
  • Patent number: 10072083
    Abstract: The present invention provides methods for isolating an active polypeptide or immunoconjugate by purification of a solution containing both the active polypeptide or immunoconjugate and an acidic variant thereof, such as a deamidated variant, using anion exchange chromatography. The present invention also provides compositions, formulations, and unit dosage forms comprising the purified polypeptide or immunoconjugate.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: September 11, 2018
    Assignee: MedImmune, LLC
    Inventors: Thomas Linke, William K. Wang, Ambarish Shah, Hasige Sathish, Alan Hunter, Christopher Thompson
  • Patent number: 10040857
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: August 7, 2018
    Assignee: MEDIMMUNE, LLC
    Inventors: Partha S. Chowdhury, David Tice, Zhan Xiao, Philipp Steiner, Krista Kinneer, Marlon Rebelatto
  • Patent number: 10016496
    Abstract: Respiratory Syncytial Virus is a common cold virus belonging to the family of paramyxovirus. RSV is virulent, easily transmissible and the most common cause of lower respiratory tract disease in children of less than 2 years of age. Up to 98% of children attending day care will be infected in a single RSV season. Between 0.5% and 3.2% of children with RSV infection require hospitalization. Approximately 90,000 hospital admissions and 4500 deaths per year were reported in United States. Major risk factors for hospitalization due to RSV are premature birth, chronic lung disease, congenital heart disease, compromised immunity, and age younger than 6 weeks in otherwise healthy children.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: July 10, 2018
    Assignee: MedImmune, LLC
    Inventor: Nancy Ulbrandt
  • Patent number: 10011660
    Abstract: Provided are polypeptides comprising a variant IgG Fc domain, wherein the polypeptides exhibit reduced or ablated effector functions (e.g., ADCC and/or CDC) and increased stability and plasma half-life compared to a parent polypeptide. Also provided are compositions, methods of treatment, and methods to diminish Fc-induced effector function in a parent polypeptide.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: July 3, 2018
    Assignee: MedImmune, LLC
    Inventors: Ping Tsui, Martin Borrok, II, William Dall'Acqua
  • Patent number: 10006026
    Abstract: Disclosed herein is a method for producing a recombinant polypeptide in a mammalian cell culture in which the mammalian cells have a modified microRNA activity level. In one embodiment, a microRNA activity level is increased. In another embodiment, a microRNA activity level is decreased. In a more particular embodiment, the mammalian cells have a reduced miRNA-let-7a activity level.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: June 26, 2018
    Assignee: MedImmune, LLC
    Inventors: Katie Streicher, Jonathan Jacobs, Robert W. Georgantas, III, Lydia Greenlees, Koustubh Ranade, Michael Bowen
  • Patent number: 9957312
    Abstract: Fusion proteins containing B7-H4 polypeptides are disclosed. The B7-H4 fusion proteins can include full-length B7-H4 polypeptides, or can contain a fragment of a full-length B7-H4 polypeptide, including some or all of the extracellular domain of the B7-H4 polypeptide. Methods for using the fusion proteins to downregulate T cell activation and for the treatment of inflammatory and autoimmune diseases and disorders are also disclosed. The B7-H4 fusion proteins are useful for treating inflammation by inhibiting or reducing differentiation, proliferation, activity, and/or cytokine production and/or secretion by ThI, ThI 7, Th22, and/or other cells that secrete, or cause other cells to secrete, inflammatory molecules, including, but not limited to, IL-1?, TNF-?, TGF-beta, IFN-?, IL-17, IL-6, IL-23, IL-22, IL-21, and MMPs; or enhancing IL-IO secretion by Tregs, increasing the differentiation of Tregs, increasing the number of Tregs, or combinations thereof.
    Type: Grant
    Filed: April 6, 2015
    Date of Patent: May 1, 2018
    Assignee: MedImmune, LLC
    Inventors: Solomon Langermann, Linda Liu, Joseph R. Podojil, Stephen D. Miller, Shannon Marshall
  • Publication number: 20180079813
    Abstract: Antibodies and humanized variants thereof and their antigen-binding fragments and other molecules that are capable of immunospecifically binding to the B7-H7 counter-receptor, and their uses in enhancing immune responses and the treatment and diagnosis of cancer and other diseases are provided.
    Type: Application
    Filed: September 19, 2017
    Publication date: March 22, 2018
    Applicants: MEDIMMUNE, LLC, THE JOHNS HOPKINS UNIVERSITY
    Inventors: SOLOMON LANGERMANN, LINDA LIU, SHENG YAO, LIEPING CHEN
  • Patent number: 9920124
    Abstract: The present invention provides methods of preparing active immunoconjugates, including anti-CD22 immunoconjugates. Suitably, the methods include a fed-batch refolding process and/or column stripping process that result in an increase in yield of the immunoconjugate over other processes that do not utilize the methods.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: March 20, 2018
    Assignee: MedImmune, LLC
    Inventors: Alan Hunter, Thomas Linke, Timothy Pabst, Michaela Wendeler, Xiangyang Wang, Christopher Thompson, Guoling Xi, Andrew Fulton
  • Patent number: 9913894
    Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.
    Type: Grant
    Filed: July 13, 2015
    Date of Patent: March 13, 2018
    Assignee: MedImmune, LLC
    Inventors: Guillermo Tous, Mark Schenerman, Jose Casas-Finet, Ziping Wei, David Pfarr
  • Publication number: 20180066056
    Abstract: Antibodies and humanized variants thereof and their antigen-binding fragments and other molecules that are capable of immunospecifically binding to the B7-H7 counter-receptor, and their uses in enhancing immune responses and the treatment and diagnosis of cancer and other diseases are provided.
    Type: Application
    Filed: September 19, 2017
    Publication date: March 8, 2018
    Applicants: MEDIMMUNE, LLC, THE JOHNS HOPKINS UNIVERSITY
    Inventors: SOLOMON LANGERMANN, LINDA LIU, SHENG YAO, LIEPING CHEN
  • Patent number: D821572
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: June 26, 2018
    Assignee: MedImmune, LLC
    Inventors: Corbin Zean Clawson, Roger Wongjung Liu, Janardhanan Anand Subramony
  • Patent number: D822199
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: July 3, 2018
    Assignee: MedImmune, LLC
    Inventors: Corbin Zean Clawson, Roger Wongjung Liu, Janardhanan Anand Subramony